Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

152.31 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 152.31
Bid (Size) 101.00 (1)
Ask (Size) 160.00 (1)
Prev. Close 152.31
Today's Range 152.31 - 152.31
52wk Range 117.64 - 189.00
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
Jazz Pharmaceuticals's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between... 
Via Benzinga

Performance

YTD
+16.00%
+16.00%
1 Month
-7.17%
-7.17%
3 Month
+5.43%
+5.43%
6 Month
+10.40%
+10.40%
1 Year
-13.85%
-13.85%

More News

Read More
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval?
Via Benzinga
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
Via Benzinga
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Via Benzinga
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate
Via Benzinga
Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY
Via Benzinga
Jazz Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End
Via Benzinga
Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent
Via Investor's Business Daily
Avicanna's Cannabinoid Drugs To Reach Brazil Via Its First 'Big Pharma' Deal
Via Benzinga
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Via Benzinga
Expert Ratings For Jazz Pharmaceuticals
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Via Benzinga
Why Axsome Therapeutics Stock Is Trading Higher
Via Benzinga
Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio
Via Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Via Benzinga
Jazz Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma
Via Benzinga
Expert Ratings For Jazz Pharmaceuticals
Via Benzinga
Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.